Summary of Research: Ten-Year Safety and Clinical Benefit from Open-Label Etanercept Treatment in Children and Young Adults with Juvenile Idiopathic Arthritis

Jelena Vojinović; Ivan Foeldvari; Joke Dehoorne; Valda Stanevica; Paediatric Rheumatology International Trials Organisation (PRINTO)

doi:10.1007/s40744-024-00703-z

Summary of Research: Ten-Year Safety and Clinical Benefit from Open-Label Etanercept Treatment in Children and Young Adults with Juvenile Idiopathic Arthritis

Jelena Vojinović, Ivan Foeldvari, Joke Dehoorne, Valda Stanevica, Paediatric Rheumatology International Trials Organisation (PRINTO)

Rīga Stradiņš University

Research output: Contribution to journal › Article › peer-review

Abstract

This is a summary of the original article 'Ten-year safety and clinical benefit from open label etanercept treatment in children and young adults with juvenile idiopathic arthritis'. Juvenile idiopathic arthritis (JIA) usually appears before the age of 16. JIA causes pain, swelling, and stiffness in the joints. People with JIA receive treatment for several years until the disease goes into prolonged remission. Therefore, the long-term safety of these treatments is an important topic. Etanercept is a treatment for JIA, which acts on the body's immune system to reduce arthritis. This summary of research article describes safety and how well etanercept works in children with JIA taking it for up to 10 years.

Original language	English
Journal	Rheumatology and Therapy
DOIs	https://doi.org/10.1007/s40744-024-00703-z
Publication status	E-pub ahead of print - 12 Sept 2024

Field of Science*

3.2 Clinical medicine

Publication Type*

1.1. Scientific article indexed in Web of Science and/or Scopus database

Access to Document

10.1007/s40744-024-00703-z

Summary of ResearchFinal published version, 886 KB

Cite this

Vojinović, J., Foeldvari, I., Dehoorne, J., Stanevica, V., & Paediatric Rheumatology International Trials Organisation (PRINTO) (2024). Summary of Research: Ten-Year Safety and Clinical Benefit from Open-Label Etanercept Treatment in Children and Young Adults with Juvenile Idiopathic Arthritis. Rheumatology and Therapy. Advance online publication. https://doi.org/10.1007/s40744-024-00703-z

@article{7f2fe96304264736b06c0c18e9c1773b,

title = "Summary of Research: Ten-Year Safety and Clinical Benefit from Open-Label Etanercept Treatment in Children and Young Adults with Juvenile Idiopathic Arthritis",

abstract = "This is a summary of the original article 'Ten-year safety and clinical benefit from open label etanercept treatment in children and young adults with juvenile idiopathic arthritis'. Juvenile idiopathic arthritis (JIA) usually appears before the age of 16. JIA causes pain, swelling, and stiffness in the joints. People with JIA receive treatment for several years until the disease goes into prolonged remission. Therefore, the long-term safety of these treatments is an important topic. Etanercept is a treatment for JIA, which acts on the body's immune system to reduce arthritis. This summary of research article describes safety and how well etanercept works in children with JIA taking it for up to 10 years.",

author = "Jelena Vojinovi{\'c} and Ivan Foeldvari and Joke Dehoorne and Violeta Panaviene and Gordana Susic and Gerd Horneff and Valda Stanevica and Katarzyna Kobusinska and Zbigniew Zuber and Bogna Dobrzyniecka and Tadej Avcin and Cecilia Borlenghi and Edmund Arthur and Chuanbo Zang and Vassilis Tsekouras and Bonnie Vlahos and Alberto Martini and Nicolino Ruperto and {Paediatric Rheumatology International Trials Organisation (PRINTO)}",

note = "Publisher Copyright: {\textcopyright} The Author(s) 2024.",

year = "2024",

month = sep,

day = "12",

doi = "10.1007/s40744-024-00703-z",

language = "English",

journal = "Rheumatology and Therapy",

issn = "2198-6576",

publisher = "Adis International Ltd",

}

TY - JOUR

T1 - Summary of Research

T2 - Ten-Year Safety and Clinical Benefit from Open-Label Etanercept Treatment in Children and Young Adults with Juvenile Idiopathic Arthritis

AU - Vojinović, Jelena

AU - Foeldvari, Ivan

AU - Dehoorne, Joke

AU - Panaviene, Violeta

AU - Susic, Gordana

AU - Horneff, Gerd

AU - Stanevica, Valda

AU - Kobusinska, Katarzyna

AU - Zuber, Zbigniew

AU - Dobrzyniecka, Bogna

AU - Avcin, Tadej

AU - Borlenghi, Cecilia

AU - Arthur, Edmund

AU - Zang, Chuanbo

AU - Tsekouras, Vassilis

AU - Vlahos, Bonnie

AU - Martini, Alberto

AU - Ruperto, Nicolino

AU - Paediatric Rheumatology International Trials Organisation (PRINTO)

PY - 2024/9/12

Y1 - 2024/9/12

N2 - This is a summary of the original article 'Ten-year safety and clinical benefit from open label etanercept treatment in children and young adults with juvenile idiopathic arthritis'. Juvenile idiopathic arthritis (JIA) usually appears before the age of 16. JIA causes pain, swelling, and stiffness in the joints. People with JIA receive treatment for several years until the disease goes into prolonged remission. Therefore, the long-term safety of these treatments is an important topic. Etanercept is a treatment for JIA, which acts on the body's immune system to reduce arthritis. This summary of research article describes safety and how well etanercept works in children with JIA taking it for up to 10 years.

AB - This is a summary of the original article 'Ten-year safety and clinical benefit from open label etanercept treatment in children and young adults with juvenile idiopathic arthritis'. Juvenile idiopathic arthritis (JIA) usually appears before the age of 16. JIA causes pain, swelling, and stiffness in the joints. People with JIA receive treatment for several years until the disease goes into prolonged remission. Therefore, the long-term safety of these treatments is an important topic. Etanercept is a treatment for JIA, which acts on the body's immune system to reduce arthritis. This summary of research article describes safety and how well etanercept works in children with JIA taking it for up to 10 years.

UR - http://www.scopus.com/inward/record.url?scp=85203790476&partnerID=8YFLogxK

U2 - 10.1007/s40744-024-00703-z

DO - 10.1007/s40744-024-00703-z

M3 - Article

C2 - 39264536

SN - 2198-6576

JO - Rheumatology and Therapy

JF - Rheumatology and Therapy

ER -

Vojinović J, Foeldvari I, Dehoorne J, Stanevica V, Paediatric Rheumatology International Trials Organisation (PRINTO). Summary of Research: Ten-Year Safety and Clinical Benefit from Open-Label Etanercept Treatment in Children and Young Adults with Juvenile Idiopathic Arthritis. Rheumatology and Therapy. 2024 Sept 12. Epub 2024 Sept 12. doi: 10.1007/s40744-024-00703-z

Summary of Research: Ten-Year Safety and Clinical Benefit from Open-Label Etanercept Treatment in Children and Young Adults with Juvenile Idiopathic Arthritis

Abstract

Field of Science*

Publication Type*

Access to Document

Other files and links

Fingerprint

Cite this